(NASDAQ: ONC) Beone Medicines's forecast annual revenue growth rate of 20.11% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Beone Medicines's revenue in 2025 is $4,175,868,000.On average, 6 Wall Street analysts forecast ONC's revenue for 2025 to be $7,196,256,431,118, with the lowest ONC revenue forecast at $7,005,890,265,746, and the highest ONC revenue forecast at $7,381,416,312,360. On average, 6 Wall Street analysts forecast ONC's revenue for 2026 to be $8,702,520,031,631, with the lowest ONC revenue forecast at $8,261,994,018,825, and the highest ONC revenue forecast at $9,027,500,216,238.
In 2027, ONC is forecast to generate $10,142,050,576,761 in revenue, with the lowest revenue forecast at $9,004,626,245,536 and the highest revenue forecast at $11,157,445,782,569.